BeiGene Ltd ADR [BGNE] stock prices are up 5.31% to $246.04 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BGNE shares have gain 12.65% over the last week, with a monthly amount glided 28.43%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BeiGene Ltd ADR [NASDAQ: BGNE] stock has seen the most recent analyst activity on September 18, 2024, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $288. On September 12, 2023, Macquarie initiated with a Outperform rating and assigned a price target of $259 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $287 on August 17, 2023. Citigroup initiated its recommendation with a Buy and recommended $275 as its price target on July 17, 2023. Bernstein downgraded its rating to Mkt Perform for this stock on June 30, 2023, and downed its price target to $196. In a note dated January 12, 2023, Daiwa Securities initiated an Buy rating and provided a target price of $308 on this stock.
The stock price of BeiGene Ltd ADR [BGNE] has been fluctuating between $126.97 and $238.80 over the past year. Currently, Wall Street analysts expect the stock to reach $255.8 within the next 12 months. BeiGene Ltd ADR [NASDAQ: BGNE] shares were valued at $246.04 at the most recent close of the market. An investor can expect a potential return of 3.97% based on the average BGNE price forecast.
Analyzing the BGNE fundamentals
The BeiGene Ltd ADR [NASDAQ:BGNE] reported sales of 3.10B for trailing twelve months, representing a surge of 56.09%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.29%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.15 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 243.35 points at the first support level, and at 240.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 248.45, and for the 2nd resistance point, it is at 250.85.
Ratios To Look Out For
It’s worth pointing out that BeiGene Ltd ADR [NASDAQ:BGNE]’s Current Ratio is 1.98. As well, the Quick Ratio is 1.75, while the Cash Ratio is 1.35. Considering the valuation of this stock, the price to sales ratio is 7.73, the price to book ratio is 7.75.
Transactions by insiders
Recent insider trading involved Lee Chan Henry, SVP, General Counsel, that happened on Sep 30 ’24 when 1202.0 shares were sold. Global Head of R&D, Wang Lai completed a deal on Sep 27 ’24 to sell 5000.0 shares. Meanwhile, Officer CHAN LEE bought 1202.0 shares on Sep 30 ’24.
